Outcome of the Board Meeting held on February 13, 2026
Awaiting price reaction for this filing.
Insilco Ltd, which has been under voluntary liquidation since June 25, 2021, reported its Q3 FY26 (ended Dec 31, 2025) results. The company continues to have zero revenue from operations, with only Rs 10 lakhs of other income in the quarter. It posted a loss of Rs 49 lakhs for Q3 and Rs 235 lakhs for the 9-month period, widening from Rs 160 lakhs a year earlier. The financial statements are explicitly not prepared on a going-concern basis. The Board accepted the resignation of MD Ms. Chaitali Talele and appointed Ms. Shivangi Negi as the new MD (without remuneration) for 5 years from Feb 14, 2026, plus Ms. Deepa Jha as an Additional Director. The Liquidator provided an update on the winding-up process: liquidation was completed on July 18, 2025, liquidation proceeds of Rs 4.58 per share were distributed in March 2025, and the dissolution application is pending before NCLT Allahabad, with the next hearing on Feb 12, 2026. BSE trading in the stock has been suspended since Oct 7, 2022.
For shareholders, this filing confirms the company remains in its final wind-down phase with no operating business and ongoing legal/admin delays in dissolving the entity. The stock is already suspended from trading, so there is no immediate price impact, but pending NCLT clearance of the dissolution application is the key milestone for any residual shareholder action.